William Powers, DO
Pulmonary Disease · Beckley, WVNPI 1871601377
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $286 and has fallen 80.7% since, to $55 in 2025. That places this record below the midpoint for pulmonary disease clinicians in WV, where the typical reported total is $1,097.
Across 33 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$129
- AstraZeneca$88
- Kyowa Kirin, Inc.$57
- Novo Nordisk$52
- Lilly USA, LLC$46
- Boehringer Ingelheim$40
- plus $177 from 7 others
What the payments were for
- Food & beverage$589100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $129 |
| AstraZeneca | 4 | $88 |
| Kyowa Kirin, Inc. | 3 | $57 |
| Novo Nordisk | 3 | $52 |
| Lilly USA, LLC | 3 | $46 |
| Boehringer Ingelheim | 2 | $40 |
| AbbVie | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 3 | $35 |
| Braeburn Inc. | 2 | $30 |
| GSK | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $16 |
| Pfizer | 1 | $13 |
How this compares
$589 in reported general payments places this provider in the 35th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 344 | $83,133 |
| EntrestoSacubitril/Valsartan | 74 | $21,792 |
| XareltoRivaroxaban | 68 | $19,101 |
| FarxigaDapagliflozin Propanediol | 92 | $18,049 |
| TradjentaLinagliptin | 56 | $16,594 |
| JardianceEmpagliflozin | 88 | $15,975 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $14,439 |
| VraylarCariprazine Hcl | 15 | $12,326 |
| JanuviaSitagliptin Phosphate | 50 | $7,605 |
| LinzessLinaclotide | 13 | $7,518 |
| MultaqDronedarone Hcl | 34 | $6,893 |
| Pantoprazole Sodium | 499 | $5,992 |
| Atorvastatin Calcium | 622 | $5,374 |
| Metoprolol Succinate | 318 | $3,658 |
| Sucralfate | 88 | $3,495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $83,133344 claims |
| Boehringer IngelheimTradjenta, Jardiance | $40 | $32,569144 claims |
| NovartisEntresto | $129 | $21,79274 claims |
| AbbVieVraylar, Linzess | $39 | $19,84428 claims |
| AstraZenecaFarxiga | $88 | $18,04992 claims |
| GSKTrelegy Ellipta | $23 | $14,43921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 89 pulmonary disease providers in West Virginia.
Other pulmonary disease in Beckley
- Maria BoustaniBeckley$95K
- Ramzi HaddadinBeckley$43K
- Charles PorterfieldBeckley$8K
- Shirkant BembalkarBeckley$746
- Melvin SaludesGlen Dale$255K
- Roger AbrahamsMorgantown$133K
- Salam RajjoubBridgeport$29K
- Peter KochupuraMorgantown$22K
- Phillip AguilaMartinsburg$21K
- Ryan WaddellCharleston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.